BenzingaOctober 9, 2026 at 3:09 AM NY18 Days Ago
Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom Improvement At Week 112, With No New Safety Signals
ICOTYDE clinical data highlights2High levels of skin clearance were observed at Week 112, with ≥72% of ICOTYDE-treated patients achieving a Psoriasis Area and Severity Index score (PASI)c of 90 and ≥70% achieving clear
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
